Xenetic Biosciences Q3 EPS $(0.69) Beats $(1.12) Estimate, Sales $611.17K Beat $460.00K Estimate
Portfolio Pulse from Benzinga Newsdesk
Xenetic Biosciences reported Q3 losses of $(0.69) per share, beating the analyst consensus estimate of $(1.12) by 38.39 percent. This is a 15 percent decrease over losses from the same period last year. The company also reported quarterly sales of $611.17 thousand, beating the analyst consensus estimate of $460.00 thousand by 32.86 percent, a 47.54 percent increase over sales from the same period last year.

November 10, 2023 | 1:44 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Xenetic Biosciences reported better than expected Q3 earnings and sales, which could positively impact the stock in the short term.
Xenetic Biosciences reported Q3 earnings and sales that beat analyst estimates. This positive financial performance could lead to increased investor confidence and a potential rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100